Table 2.

Maternal and Neonatal Outcomes

VariableHydroxychloroquine Group, n=47No Hydroxychloroquine Group, n=30P Value
Hypertensive disorders in pregnancya14 (30)8 (27)0.77
 Preeclampsia with severe features9 (19)7 (23)0.66
Intrauterine growth restriction1 (2)3 (10)0.29
Gestational weeks at delivery, mean ± SD35.5 ± 4.935.6 ± 4.20.88
Preterm birth <37 weeks19 (40)16 (53)0.27
Infectious complications8 (17)b5 (17)0.97
 Chorioamnionitis5 (11)2 (7)0.70
 Endometritis4 (9)3 (10)>0.99
Venous thromboembolism2 (4)0 (0)0.52
Maternal death2 (4)1 (3)>0.99
Inpatient consultation for rheumatology18 (38)3 (10)0.007
 Median number of consults (Q1-Q3)1 (1-1)2 (1-3)
Disease-related hospitalization during pregnancy20 (43)2 (7)<0.001
Neonatal compositec18 (38)15 (50)0.31
 Intrapartum fetal death2 (4)0 (0)0.52
 NICU admission >72 h16 (34)15 (50)0.16
 Mechanical ventilation >24 h2 (4)5 (17)0.10
 Suspected sepsis5 (11)1 (3)0.40
 Culture-proven early-onset sepsis2 (4)0 (0)0.52
 Neonatal death1 (2)1 (3)>0.99
 Grade III/IV intraventricular0 (0)0 (0)
  hemorrhage
 Hypoxic ischemic encephalopathy1 (2)0 (0)>0.99
 Respiratory distress syndrome4 (9)4 (13)0.70
 Seizures0 (0)0 (0)
 Cardiopulmonary resuscitation1 (2)0 (0)>0.99
 Necrotizing enterocolitis2 (4)0 (0)0.52
  • Notes: Data are presented as n (%) unless otherwise indicated. Because no maternal pregnancy or neonatal morbidities were statistically significant, no odds ratios or adjustments for age and parity are presented. The adjusted odds ratio of maternal disease-related morbidity is presented in the body of the text.

  • NICU, neonatal intensive care unit.

  • aHypertensive disorders in pregnancy denotes any diagnosis of gestational hypertension or preeclampsia.

  • bOne patient was treated for both chorioamnionitis and endometritis.

  • cNeonatal composite includes the 12 listed outcomes.